Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate CusatuzumabBenzinga • 06/07/21
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
argenx Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/21
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021GlobeNewsWire • 05/07/21
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/04/21
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/04/21
Argenx's Efgartigimod US Application In Neuromuscular Disorder Accepted For ReviewBenzinga • 03/02/21
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021GlobeNewsWire • 02/25/21
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim AnalysisGlobeNewsWire • 02/01/21
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOsSeeking Alpha • 01/10/21
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology PipelineGlobeNewsWire • 01/08/21
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient ExperiencePRNewsWire • 11/17/20